EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Epidemiologic Characteristics Determining the Choice of Direct-Acting Antiviral Therapy in HCV Patients: An Italian Real-World Evidence Study

Nicola Pugliese iD, Fabio Conti, Valerio Rosato iD, Paolo Gallo iD, Stefano Gitto iD, Marco Riglietta, Francesca Frigerio iD, Valentina Perrone iD, Chiara Veronesi iD, Maria Cappuccilli iD, Luca Degli Esposti iD, Alessandra Mangia iD und 1 weitere

Pathogens · 2025

DOI: 10.3390/pathogens14111177 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens, 2025. Verfasst von Nicola Pugliese und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, MI, Italy. Hauptthemen laut MEDLINE: Antiviral Agents, Hepacivirus, Hepatitis C, Chronic, Hepatitis C. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences (Italy), Gilead Science, Italy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pangenotypic direct-acting antivirals (pDAAs) have transformed hepatitis C virus (HCV) treatment. In Italy, sofosbuvir/velpatasvir (SOF/VEL) and glecaprevir/pibrentasvir (GLE/PIB) are available. While both show similar efficacy, differences in patient profiles and potential drug–drug interactions (DDIs) may influence treatment choice. This study examined factors affecting pDAA selection and potential prescribing gaps. Using administrative databases (2018–2023) covering 3.7 million citizens, HCV patients were divided into SOF/VEL and GLE/PIB cohorts and compared by demographic, clinical, and therapeutic data. Among 5565 patients, 2837 (51%) received SOF/VEL and 2728 (49%) received GLE/PIB. SOF/VEL patients were older (60.8 vs. 57.6 years, p < 0.001) and had more comorbidities: diabetes (24% vs. 17%), mental disorders (22% vs. 14%), cancer (14% vs. 9%), and cardiovascular disease (31% vs. 22%). Hospitalization rates were higher (19% vs. 13%), as were exemption codes for chronic hepatitis (58% vs. 50%) and hypertension (32% vs. 23%). Polypharmacy was more common with SOF/VEL; 25% used ≥10 non-pDAA drugs (vs. 17%), and mean medications per patient were higher (6.3 ± 5.6 vs. 4.9 ± 5.2). SOF/VEL was often used for older, frailer patients, likely due to a more favourable DDI profile. These prescribing trends highlight the importance of tailoring pDAA choice to patient comorbidity profiles, ensuring appropriate and individualized HCV treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepacivirusHepatitis C, ChronicHepatitis CHumansMaleItalyMiddle AgedFemaleAgedSofosbuvirQuinoxalinesPyrrolidinesDrug InteractionsBenzimidazolesHeterocyclic Compounds, 4 or More RingsSulfonamidesDrug CombinationsAdultDrug Therapy, Combination

Stichwörter der Autor:innen

drug–drug interactions (DDIs)glecaprevir/pibrentasvirhepatitis C virus (HCV)pangenotypic direct-acting antiviralssofosbuvir/velpatasvir

Substanzen

Antiviral AgentsSofosbuvirQuinoxalinesPyrrolidinesBenzimidazolesHeterocyclic Compounds, 4 or More RingsSulfonamidesDrug Combinations

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, MI, Italy.
  • Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy.
  • Dipartimento di Medicina Interna, Ospedale degli Infermi di Faenza, 48018 Faenza, FC, Italy.
  • Unità di Medicina Interna ed Epatologia, Ospedale Evangelico Villa Betania, 80147 Napoli, NA, Italy.
  • UOS Medicina Clinica ed Epatologia, Policlinico Universitario Campus Bio-Medico, 00128 Roma, RM, Italy.
  • Department of Experimental and Clinical Medicine, University of Florence, 50141 Firenze, FI, Italy.

ORCID-Profile: Nicola Pugliese, Valerio Rosato, Paolo Gallo, Stefano Gitto, Francesca Frigerio, Valentina Perrone, Chiara Veronesi, Maria Cappuccilli, Luca Degli Esposti, Alessandra Mangia, Loreta A Kondili

Förderung

  • Gilead Sciences (Italy)
  • Gilead Science, Italy

Zitieren

APA

Pugliese, N., Conti, F., Rosato, V., Gallo, P., Gitto, S., Riglietta, M., Frigerio, F., Perrone, V., Veronesi, C., Cappuccilli, M., Degli Esposti, L., Mangia, A., & Kondili, L. A. (2025). Epidemiologic Characteristics Determining the Choice of Direct-Acting Antiviral Therapy in HCV Patients: An Italian Real-World Evidence Study. Pathogens. https://doi.org/10.3390/pathogens14111177

Vancouver

Pugliese N, Conti F, Rosato V, Gallo P, Gitto S, Riglietta M, et al. Epidemiologic Characteristics Determining the Choice of Direct-Acting Antiviral Therapy in HCV Patients: An Italian Real-World Evidence Study. Pathogens. 2025. doi:10.3390/pathogens14111177

BibTeX
@article{Pugliese2025,
  author = {Pugliese, Nicola and Conti, Fabio and Rosato, Valerio and Gallo, Paolo and Gitto, Stefano and Riglietta, Marco and Frigerio, Francesca and Perrone, Valentina and Veronesi, Chiara and Cappuccilli, Maria and Degli Esposti, Luca and Mangia, Alessandra and Kondili, Loreta A},
  title = {Epidemiologic Characteristics Determining the Choice of Direct-Acting Antiviral Therapy in HCV Patients: An Italian Real-World Evidence Study},
  journal = {Pathogens},
  year = {2025},
  doi = {10.3390/pathogens14111177}
}
Kostenlos starten →